MK-2118
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-2118, covering 2024-07-24 to 2024-07-24. Get the full timeline:
Most recent: Clinical Trial Update: Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced/Metastatic Solid Tumors or Lymphomas (MK-2118-001) [Phase 1]